In a differentially expressed gene (DEG) set analysis, 10 out of 13 predefined major cancer pathways were shown to correlate with the AIMP2-DX2/AIMP2 expression ratio to different degrees and directions among 14 cancer types (Fig. 2c), while the other 9 cancer types (ovarian cancer, breast invasive carcinoma, colon adenocarcinoma, melanoma, rectum adenocarcinoma, kidney renal clear cell carcinoma, prostate adenocarcinoma, head and neck squamous cell carcinoma, and uterine corpus endometrial carcinoma) did not show clear correlations. This evidence concerns the gene AIMP2 and ovarian carcinoma.